BABA
Alibaba Group Holding Limited
BABA's outlook is improving, though it still trails on the overall score.
EYE
National Vision Holdings, Inc.
EYE has the edge over BABA overall, supported by stronger valuation and stronger fundamentals.
BABA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Healthy |
BABA's balance sheet is currently healthy, and its revenue is stable, but its profitability and cash flow are under pressure.
EYE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Under pressure | |
| Healthy |
EYE's profitability and balance sheet are currently healthy, and its revenue is stable, but its cash flow is under pressure.
BABA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $69.66 | -26% |
| Fair | 20x | $86.59 | -8.2% |
| Current | 21x | $94.36 | — |
| Expensive | 26x | $115 | +22% |
Historical ranges are pointers, not guarantees.
BABA's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
EYE PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 16x | $18.57 | — |
| Current | 23x | $18.57 | — |
| Cheap | 28x | $22.52 | +21% |
| Fair | 50x | $40.68 | +119% |
| Expensive | 103x | $83.20 | +348% |
Historical ranges are pointers, not guarantees.
EYE has the edge over BABA in the historical PE scenario, which offers more potential upside but is not a forecast.
BABA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
BABA has the edge over EYE on the outlook, with more favorable revenue expectations.
EYE Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect EYE's earnings to grow and its profitability to improve, with its revenue holding steady.
BABA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $4.42 | -52% |
| Q1 2026 | $6.57 | -18% |
| Q4 2025 | $5.79 | -22% |
| Q3 2025 | $7.85 | +49% |
| Q2 2025 | $9.27 | +116% |
| Q1 2025 | $8.06 | +71% |
| Q4 2024 | $7.47 | +24% |
| Q3 2024 | $5.26 | -35% |
BABA's earnings per share have fallen from their peak: $4.42 over the past year, against $9.27 in mid-2025. Its recent earnings include one-off gains.
EYE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.16 | +44% |
| Q3 2026 | $0.81 | +$0.84 |
| Q2 2026 | $0.61 | +$0.79 |
| Q1 2026 | $0.57 | +$0.90 |
| Q4 2025 | $0.37 | +$0.73 |
| Q3 2025 | -$0.03 | +$0.16 |
| Q2 2025 | -$0.18 | +$0.84 |
| Q1 2025 | -$0.33 | +$0.58 |
| Q4 2024 | -$0.36 | +$0.48 |
EYE has the edge over BABA on earnings, with more consistent year-over-year improvement.
BABA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $40.2B | +8.3% |
| Q1 2026 | $36.5B | +2.9% |
| Q4 2025 | $42.7B | +1.7% |
| Q3 2025 | $37.2B | +4.8% |
| Q2 2025 | $37.2B | +1.8% |
| Q1 2025 | $35.5B | +6.6% |
| Q4 2024 | $42B | +7.6% |
| Q3 2024 | $35.5B | +5.2% |
BABA's revenue has grown year over year for 16 quarters in a row: $40.2B last quarter, up 8.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.2% | -6.9 points |
| Q1 2026 | -0.3% | -12 points |
| Q4 2025 | 7.1% | -7.6 points |
| Q3 2025 | 2.2% | -13 points |
| Q2 2025 | 14% | -0.7 points |
| Q1 2025 | 12% | +5.4 points |
| Q4 2024 | 15% | +6.1 points |
| Q3 2024 | 15% | 0 points |
BABA has the edge over EYE on profitability, with a higher operating margin.
EYE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $510.5M | +4.8% |
| Q2 2026 | $498.8M | +2.5% |
| Q1 2026 | $543.9M | +6.6% |
| Q4 2025 | $503.4M | +15% |
| Q3 2025 | $487.3M | +7.9% |
| Q2 2025 | $486.4M | +7.7% |
| Q1 2025 | $510.3M | -5.9% |
| Q4 2024 | $437.3M | -14% |
EYE's revenue has grown year over year for six quarters in a row: $511M last quarter, up 4.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.1% | +4.1 points |
| Q2 2026 | 4.3% | +0.9 points |
| Q1 2026 | 8.3% | +3.2 points |
| Q4 2025 | 1.3% | +7.2 points |
| Q3 2025 | 2% | +3.9 points |
| Q2 2025 | 3.4% | +3.3 points |
| Q1 2025 | 5.1% | +0.6 points |
| Q4 2024 | -5.8% | -3.2 points |
EYE's operating margin was 6.1% last quarter, up 4.1 points from the same quarter a year ago.
BABA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.7B | -$4.1B |
| Q1 2026 | -$2.7B | +$1.5B |
| Q4 2025 | $1B | -90% |
| Q3 2025 | -$3.2B | -254% |
| Q2 2025 | -$2.7B | -182% |
| Q1 2025 | -$4.2B | -12231% |
| Q4 2024 | $10.4B | -4.8% |
| Q3 2024 | $2.1B | -62% |
BABA's free cash flow has turned negative after years in the green: −$11.6B over the past year.
EYE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $49.3M | +63% |
| Q2 2026 | -$14.1M | -133% |
| Q1 2026 | $44.1M | +267% |
| Q4 2025 | -$11.2M | -$9.5M |
| Q3 2025 | $30.3M | +647% |
| Q2 2025 | $42.4M | +33% |
| Q1 2025 | $12M | +202% |
| Q4 2024 | -$1.7M | +$11.3M |
EYE has the edge over BABA on cash generation, producing positive trailing cash flow while its opponent burns cash.
BABA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +11.1M shares |
| 1 year | +0.9% | +21.4M shares |
| 3 years | -6.2% | -161M shares |
| 5 years | -12% | -339M shares |
| Available history | -8.4% | -221M shares |
BABA has 2.4B diluted shares, up 0.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $269.8M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BABA spent $270M buying back its own shares over the past year, after none the year before.
EYE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -533K shares |
| 1 year | -1.4% | -1.1M shares |
| 3 years | +2.4% | +1.9M shares |
| 5 years | -17% | -16.4M shares |
| Available history | -2.1% | -1.7M shares |
EYE has the edge over BABA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $21.4M |
| Q2 2026 | $20.1M |
| Q1 2026 | $10.5M |
| Q4 2025 | $650,000 |
| Q3 2025 | $876,000 |
| Q2 2025 | $55,000 |
| Q1 2025 | $1.6M |
| Q4 2024 | $273,000 |
EYE spent $53M buying back its own shares over the past year, more than ten times what it spent the year before.
BABA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.3x | Very low |
| Q4 2024 | 0.1x | Very low |
| Q3 2024 | -0.2x | Net Cash |
BABA has the edge over EYE on leverage, with a lower net debt burden relative to earnings.
EYE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.9x | Very low |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.2x | Elevated |
EYE's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
BABA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.0 | Neutral |
| Stochastic | 12.7 | Oversold |
BABA's weekly RSI is 38 (neutral) and its Stochastic is 13 (oversold).
EYE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.6 | Neutral |
| Stochastic | 33.1 | Neutral |
EYE's weekly RSI is 49 (neutral) and its Stochastic is 33 (neutral).
BABA PE vs Consumer Cyclical Sector
| Metric | BABA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 18x | 19% above |
| PE % | 60 | 47 | 13 pts above |
BABA has the edge over EYE on valuation relative to its sector.
EYE PE vs Consumer Cyclical Sector
| Metric | EYE | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 18x | 27% above |
| PE % | 7 | 47 | 40 pts below |
EYE is trading at 23x earnings, a 27% premium to the Consumer Cyclical sector's median of 18x.
BABA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $104.7 | 9.9% below |
| 20 week MA | $111.1 | 15% below |
| 50 week MA | $128.0 | 26% below |
| 100 week MA | $127.7 | 26% below |
| 200 week MA | $106.4 | 11% below |
BABA is in a downtrend: it's below all five of its weekly moving averages, and 11% below its 200-week average.
EYE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.4 | 7% above |
| 20 week MA | $18.4 | 0.7% above |
| 50 week MA | $22.0 | 16% below |
| 100 week MA | $20.5 | 9.5% below |
| 200 week MA | $19.7 | 5.6% below |
EYE has the edge over BABA on trend strength, trading above more of its moving averages.
BABA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $215.5 | $222.0 | +3% |
| 2021 | $222.0 | $118.7 | -47% |
| 2022 | $118.7 | $85.7 | -28% |
| 2023 | $85.7 | $77.5 | -9.5% |
| 2024 | $77.5 | $85.1 | +9.7% |
| 2025 | $85.1 | $152.2 | +79% |
| 2026 YTD | $152.2 | $94.4 | -38% |
BABA has finished lower in three of the last six years. It's down 38% so far in 2026.
EYE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.1 | $47.3 | +43% |
| 2021 | $47.3 | $47.8 | +1.1% |
| 2022 | $47.8 | $38.7 | -19% |
| 2023 | $38.7 | $20.9 | -46% |
| 2024 | $20.9 | $10.6 | -49% |
| 2025 | $10.6 | $28.0 | +165% |
| 2026 YTD | $28.0 | $18.6 | -34% |
EYE has the edge over BABA on returns for 2026, with the stronger performance.